Kristy Perez
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2016First federal award
$12.2MFederal grants as PI13 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
13 awards · $12.2M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 17, 2026 | NIH | SBIR Phase II CivaDerm Non-Melanoma Skin Cancer Radiation Therapy Device | $1.2M | CIVATECH ONCOLOGY, INC. |
| Jun 25, 2025 | NIH | SBIR Phase II Commercializing CivaSheet for Pancreatic Cancer Patients | $1.0M | CIVATECH ONCOLOGY, INC. |
| Jun 14, 2024 | NIH | SBIR Phase II Commercializing CivaSheet for Pancreatic Cancer Patients | $1.1M | CIVATECH ONCOLOGY, INC. |
| Jul 8, 2023 | NIH | SBIR Phase II Commercializing CivaSheet for Pancreatic Cancer Patients | $1.9M | CIVATECH ONCOLOGY, INC. |
| May 18, 2021 | NIH | SBIR Phase II Administrative Supplement for the Evaluation of the novel, uni-directional, Pd-103 CivaSheet for Lung Cancer | $220K | CIVATECH ONCOLOGY, INC. |
| Sep 2, 2020 | NIH | SBIR Phase II Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Lung Cancer | $595 | CIVATECH ONCOLOGY, INC. |
| Aug 15, 2019 | NIH | SBIR Phase II Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Lung Cancer | $802K | CIVATECH ONCOLOGY, INC. |
| Sep 14, 2018 | NIH | SBIR Phase II Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Lung Cancer | $1.2M | CIVATECH ONCOLOGY, INC. |
| Sep 1, 2018 | NIH | SBIR Phase II Administrative Supplement for the Evaluation of the novel, uni-directional, Pd-103 CivaSheet for Lung Cancer | $2.2M | CIVATECH ONCOLOGY, INC. |
| Aug 27, 2018 | NIH | SBIR Phase II Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Pancreatic Cancers | $570K | CIVATECH ONCOLOGY, INC. |
| Sep 15, 2017 | NIH | SBIR Phase II Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Lung Cancer | $297K | CIVATECH ONCOLOGY, INC. |
| Sep 15, 2017 | NIH | SBIR Phase II Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Pancreatic Cancers | $1.5M | CIVATECH ONCOLOGY, INC. |
| Sep 15, 2016 | NIH | SBIR Phase II Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Pancreatic Cancers | $300K | CIVATECH ONCOLOGY, INC. |
Peer ranks
Federal funding#46
Awards as PI#77
Patents#505
Companies
- CIVATECH ONCOLOGY, INC.Linked by awards · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.